Stocktoria
Adaptimmune Therapeutics PLC ADAPY
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-05-06
Adaptimmune Therapeutics PLC statistics & valuation
Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -38.6% | -231.8% | -604.0% | -2638.6% | -3370.5% | -12457.2% | -138.4% | -213.2% | -512.7% | -249.6% |
| Net margin | -39.8% | -188.9% | -609.5% | -2571.0% | -3286.8% | -12225.0% | -160.5% | -185.4% | -504.1% | -223.5% |
| FCF margin | -41.6% | -241.5% | -630.9% | 35.0% | -1413.1% | -10169.3% | -182.0% | -208.7% | -420.3% | -352.0% |
| Return on assets | -28.8% | -40.3% | -50.3% | -33.7% | -28.8% | -75.6% | -34.5% | -24.9% | -30.5% | -7.3% |
| Return on equity | -597.6% | -288.2% | -202.1% | -76.8% | -38.1% | -110.9% | -38.7% | -34.6% | -43.1% | -8.5% |
| Debt / equity | 4.58× | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.92 | 2.85 | 3.96 | 6.64 | 10.19 | 3.51 | 9.46 | 3.10 | 4.94 | 11.02 |
Source: SEC EDGAR filings · CIK 0001621227 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.